Krystal Biotech (NASDAQ:KRYS) Upgraded at The Goldman Sachs Group

Krystal Biotech (NASDAQ:KRYS) was upgraded by research analysts at The Goldman Sachs Group to a “strong-buy” rating in a note issued to investors on Thursday, Zacks reports.

Several other research firms also recently weighed in on KRYS. HC Wainwright increased their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. TD Cowen upped their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 price target on shares of Krystal Biotech in a research report on Monday, July 13th. Royal Bank Of Canada started coverage on shares of Krystal Biotech in a research note on Friday, August 14th. They set an “outperform” rating and a $400.00 price objective on the stock. Finally, Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $377.20.

Krystal Biotech Stock Performance

Shares of KRYS opened at $344.96 on Thursday. The firm’s 50 day moving average price is $343.58 and its two-hundred day moving average price is $314.97. The firm has a market cap of $10.21 billion, a P/E ratio of 43.23 and a beta of 0.54. Krystal Biotech has a twelve month low of $158.08 and a twelve month high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, sell-side analysts anticipate that Krystal Biotech will post 7.48 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Silvant Capital Management LLC acquired a new stake in Krystal Biotech in the 2nd quarter valued at approximately $30,000. Integrated Wealth Concepts LLC bought a new position in Krystal Biotech in the 2nd quarter worth about $46,000. Western Wealth Management LLC bought a new position in Krystal Biotech during the first quarter valued at approximately $34,000. USA Financial Formulas purchased a new position in shares of Krystal Biotech in the first quarter worth $44,000. Finally, Versant Capital Management Inc raised its holdings in Krystal Biotech by 189.2% in the 2nd quarter. Versant Capital Management Inc now owns 214 shares of the company’s stock worth $80,000 after purchasing an additional 140 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.